Hims & Hers Health, Inc. filed a Form 8-K on November 9, 2026, disclosing the appointment of Dr. Andrew Huberman, age 51, to its board of directors effective November 4, 2026, along with two related commercial agreements totaling up to $9,500,000 per year in fees.

Key Highlights

  • Board expansion: The board increased its size from nine to ten directors to create the seat filled by Dr. Huberman.
  • Non-independent director: According to the filing, the board determined that Dr. Huberman does not meet the independence requirements under applicable New York Stock Exchange listing standards.
  • Director compensation: Dr. Huberman's annual cash retainer will be $50,000 and his annual equity award will have a value of $250,000, prorated from his appointment through the 2027 annual meeting.
  • Advisory agreement: Hims, Inc., a wholly-owned subsidiary, entered into a brand marketing and advisory agreement with Dr. Huberman on November 5, 2026, providing an annual advisory fee of $3,500,000 in cash for a two-year period.
  • Video content option: Under the advisory agreement, Dr. Huberman may also elect to create short-form videos for Hims' paid advertising channels for up to an additional $1,000,000 per year.
  • Marketing agreement: Also on November 5, 2026, Hims entered into a marketing services agreement with Scicomm Media LLC, a company co-founded and co-owned by Dr. Huberman, for podcast advertising services at an annual fee of $5,000,000 for up to three years.
  • Huberman's interest in marketing deal: The filing states the approximate dollar value of Dr. Huberman's interest in the marketing agreement is $2,100,000 annually.

Huberman Board Seat, Advisory Role, and Commercial Agreements at Hims & Hers

Hims & Hers Health, Inc. (NYSE:HIMS) disclosed on November 9, 2026 that its board of directors voted on November 4, 2026 to expand the board from nine to ten members and to appoint Dr. Andrew Huberman, 51, to fill the newly created seat. According to the filing, Dr. Huberman will serve until the company's 2027 annual meeting of stockholders, or sooner in the event of his death, resignation, or removal. The board determined that Dr. Huberman does not meet the independence requirements under applicable New York Stock Exchange listing standards, and the filing states he has not been appointed to any board committee and is not currently expected to be appointed to one.

Beyond the directorship, the filing disclosed two separate commercial arrangements entered into on November 5, 2026 between Dr. Huberman and Hims, Inc., the company's wholly-owned subsidiary. Under a brand marketing and advisory agreement, Dr. Huberman will provide scientific and brand marketing advisory services for a two-year period at an annual fee of $3,500,000 in cash, with the option to create short-form videos for Hims' paid advertising channels for up to an additional $1,000,000 per year. The advisory agreement, the filing states, may be terminated early only by mutual agreement or for uncured material breach.

Separately, Hims entered into a marketing services agreement with Scicomm Media LLC, described in the filing as a media company co-founded and co-owned by Dr. Huberman, under which Scicomm Media will provide podcast advertising services for up to three years at an annual fee of $5,000,000 in cash. The filing notes that the approximate dollar value of Dr. Huberman's interest in that agreement is $2,100,000 annually. The marketing agreement may be terminated for convenience by either party, effective no earlier than November 5, 2027, or for uncured material breach. The filing states that the full text of both agreements will be filed as exhibits to the company's Form 10-K for the year ending December 31, 2026.

What Was Disclosed

Hims & Hers Health disclosed the board appointment of Dr. Andrew Huberman effective November 4, 2026, along with an advisory agreement carrying an annual fee of $3,500,000 and a podcast marketing agreement with his co-owned company, Scicomm Media LLC, at $5,000,000 per year for up to three years.